Contents 3 min read
Claim and source comparison
Selected human-trial abstracts, publisher sections on plasma kinetics and FDA GRN 209 were compared. Experiments without verified randomization in the accessed source have a separate label. Not a full clinical review or independent medical approval.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Human randomized controlled trial
Kimura et al. (2007) examined heart-rate and salivary IgA responses to arithmetic stress with 200 mg L-theanine in 12 men; this was not an EEG experiment. Nobre et al. (2008) measured resting EEG alpha activity with 50 mg; this alone does not establish faster reactions or clinical anxiety treatment.
Heart rate, salivary IgA and resting EEG are different measures. They do not directly establish increased human brain GABA, general attention superiority or anxiety-disorder treatment; limits of small, acute experiments remain.
Human controlled trial; randomization not verified
Owen et al. (2008) studied 50 mg caffeine plus 100 mg L-theanine in 27 people; some attention-switching measures improved. The study used behavioral tests; it does not prove an ideal 2:1 ratio for everyone or guaranteed prevention of caffeine adverse effects.
A selected-task result does not establish an ideal ratio for everyone, long-term benefit or prevention of caffeine effects such as palpitations/anxiety. The accessed abstract does not verify randomization, so it is labelled a controlled human trial.
Source 3 · Abstract read
Human randomized controlled trial
Lyon et al. (2011) compared 400 mg/day Suntheanine with placebo for six weeks in 98 boys aged 8–12 with ADHD. Actigraphy showed improvements in some sleep-percentage/efficiency measures; sleep latency was unchanged.
Limited to a specific diagnosis, age, sex, product and short duration. This amount is not a personal pediatric dose or adult insomnia treatment; no serious harm in a short trial does not establish long-term safety.
Source 5 · Abstract read
Human pharmacokinetic study
Van der Pijl et al. (2010) studied 25–100 mg L-theanine in tea or aqueous solution in 15 healthy men. A one-compartment model estimated an elimination half-life of approximately 65 minutes and plasma peak time of approximately 50 minutes.
The profile’s approximate one-hour value rounds this plasma estimate. Peak time is not clinical onset; the model does not determine brain levels, effect duration, personal dose or timing. Authors have Unilever affiliations.
Source 6 · Full text read
Regulatory scientific assessment
FDA GRN 209 records a “no questions” response for L-theanine use up to 250 mg per serving in specified food categories. It is not drug-efficacy approval or a recommendation for 250 mg/day supplementation.
GRAS concerns specified products and food uses. This record does not establish long-term supplementation, pregnancy/breastfeeding or combined-use safety with sedatives/blood-pressure medicines; missing interaction records do not prove safety.
Source 7 · Official summary read
2026-11-11 correction: EEG, stress, caffeine-combination and pediatric sleep findings received separate limits. The approximate one-hour half-life was linked to a human plasma study; the generic dose, evidence grade and unverified sedation/blood-pressure flags were removed.
What is L-Theanine?
L-theanine is an amino acid found in tea. Small human studies examined stress, sleep and attention with caffeine; treatment of every anxiety condition or prevention of caffeine adverse effects has not been established.
Clinical Evidence
Kimura et al. (2007) examined heart-rate and salivary IgA responses to arithmetic stress with 200 mg L-theanine in 12 men; this was not an EEG experiment. Nobre et al. (2008) measured resting EEG alpha activity with 50 mg; this alone does not establish faster reactions or clinical anxiety treatment.
Heart rate, salivary IgA and resting EEG are different measures. They do not directly establish increased human brain GABA, general attention superiority or anxiety-disorder treatment; limits of small, acute experiments remain.
Owen et al. (2008) studied 50 mg caffeine plus 100 mg L-theanine in 27 people; some attention-switching measures improved. The study used behavioral tests; it does not prove an ideal 2:1 ratio for everyone or guaranteed prevention of caffeine adverse effects.
A selected-task result does not establish an ideal ratio for everyone, long-term benefit or prevention of caffeine effects such as palpitations/anxiety. The accessed abstract does not verify randomization, so it is labelled a controlled human trial.
Lyon et al. (2011) compared 400 mg/day Suntheanine with placebo for six weeks in 98 boys aged 8–12 with ADHD. Actigraphy showed improvements in some sleep-percentage/efficiency measures; sleep latency was unchanged.
Limited to a specific diagnosis, age, sex, product and short duration. This amount is not a personal pediatric dose or adult insomnia treatment; no serious harm in a short trial does not establish long-term safety.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Van der Pijl et al. (2010) studied 25–100 mg L-theanine in tea or aqueous solution in 15 healthy men. A one-compartment model estimated an elimination half-life of approximately 65 minutes and plasma peak time of approximately 50 minutes.
The profile’s approximate one-hour value rounds this plasma estimate. Peak time is not clinical onset; the model does not determine brain levels, effect duration, personal dose or timing. Authors have Unilever affiliations.
Safety and Side Effects
FDA GRN 209 records a “no questions” response for L-theanine use up to 250 mg per serving in specified food categories. It is not drug-efficacy approval or a recommendation for 250 mg/day supplementation.
GRAS concerns specified products and food uses. This record does not establish long-term supplementation, pregnancy/breastfeeding or combined-use safety with sedatives/blood-pressure medicines; missing interaction records do not prove safety.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Gut-Brain Axis and Cognitive Performance
The brain makes decisions, but the gut also talks. It has now become one of the most exciting areas of research in neuroscience, where the gut microbiome, which consists of billions of microorganisms, can affect mood, anxiety level and cognitive performance. The evidence is still developing – but the picture is quite striking.
- Caffeine and L-Theanine: Attention Studies and Their Limits
Small studies have examined some attention measures; a universal ideal ratio, prevention of caffeine side effects or safe use for everyone has not been established.
- Nootropic Stacks: Evidence and Risks of Five Combinations
Compare evidence and interaction risks for caffeine–L-theanine and other combinations; single-ingredient findings do not prove clinical synergy for every stack.
- Sleep and Nootropics: Human Studies and Limits
Melatonin, magnesium and other supplements have been studied using different sleep measures; subjective improvement is not proof of deeper sleep or a safe nightly protocol.
- Getting Started with Nootropics: Evidence and Safety Limits
Assess product form, study population and drug interactions; beginner trios, titration and on-off schedules are not protocols established for everyone.
Research and safety news
- · Research
Small blackcurrant blend trial finds selective attention changes in older adultsA crossover trial analyzed 26 older adults after four-week periods of a blackcurrant, L-theanine and pine-bark blend or placebo. Attention-task false alarms declined, but memory and fatigue findings were not significant after multiple-testing correction; the blend cannot isolate an ingredient.
Sources
- Kimura K, et al. (2007). L-Theanine reduces psychological and physiological stress responses. Biological Psychology, 74(1), 39–45. PubMed · PMID 16930802
- Nobre AC, et al. (2008). L-Theanine, a natural constituent in tea, and its effect on mental state. Asia Pacific Journal of Clinical Nutrition, 17(S1), 167–168. PubMed · PMID 18296328
- Owen GN, et al. (2008). The combined effects of L-Theanine and caffeine on cognitive performance and mood. Nutritional Neuroscience, 11(4), 193–198. PubMed · PMID 18681988
- Ritsner MS, et al. (2011). L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. Journal of Clinical Psychiatry, 72(1), 34–42. PubMed · PMID 21208586
- Lyon MR, et al. (2011). The effects of L-theanine (Suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. Alternative Medicine Review, 16(4), 348–354. PubMed · PMID 22214254
- van der Pijl PC, Chen L, Mulder TPJ. (2010). Human disposition of L-theanine in tea or aqueous solution. Journal of Functional Foods, 2(4), 239–244. https://doi.org/10.1016/j.jff.2010.08.001 Publisher record · DOI · Elsevier
- US Food and Drug Administration. GRN No. 209: L-theanine. https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=209 US Food and Drug Administration
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
L-theanine is an amino acid found in tea. Small human studies examined stress, sleep and attention with caffeine; treatment of every anxiety condition or prevention of caffeine adverse effects has not been established.
Owen et al. (2008) studied 50 mg caffeine plus 100 mg L-theanine in 27 people; some attention-switching measures improved. The study used behavioral tests; it does not prove an ideal 2:1 ratio for everyone or guaranteed prevention of caffeine adverse effects.
GRAS concerns specified products and food uses. This record does not establish long-term supplementation, pregnancy/breastfeeding or combined-use safety with sedatives/blood-pressure medicines; missing interaction records do not prove safety.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.
No established timeframe